A Phase III Study of NK105 in Patients With Breast Cancer
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
To verify the non-inferiority of NK105, a paclitaxel-incorporating micellar nanoparticle, to
paclitaxel in terms of the progression-free survival in patients with metastatic or recurrent
breast cancer.